UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News:
Orexo (STO:ORX)
Strong Zubsolv® and Abstral® revenue growth.
Third quarter 2016
· Total net revenues MSEK 181.9 (139.5).
